Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.73
Shares Outstanding14.6M
Average Volume (10 days)97.9K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.69)
Sales (TTM)$10.67
Book Value (MRQ)$18.47
Cash Flow (TTM)($0.34)
Cash (MRQ)$7.20

Analyst Views

Current Mean RecommendationBuy
Strong Buy1
 
Buy0
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Anne Nunes
SVP, Chief Operations Officer
(732)
Dispose
Oct 1, 2023
Richard Stephen
Director
6,500
Acquire
Jun 14, 2023
Vogt Susan
Director
6,500
Acquire
Jun 14, 2023
Thompson Jeffery
Director
6,500
Acquire
Jun 14, 2023
Larsen Glenn
Director
6,500
Acquire
Jun 14, 2023

Recent SEC Filings

Company Events
Feb 26, 2024
Amended >= 5% Acquisition
Feb 13, 2024
Amended >= 5% Acquisition
Feb 9, 2024
Amended >= 5% Acquisition
Feb 9, 2024
Amended >= 5% Acquisition
Jan 24, 2024
To Top